FY2023 EPS Estimates for Mirum Pharmaceuticals, Inc. Decreased by Analyst (NASDAQ:MIRM)

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) – Equities researchers at HC Wainwright dropped their FY2023 EPS estimates for Mirum Pharmaceuticals in a research note issued on Tuesday, February 27th. HC Wainwright analyst E. Arce now forecasts that the company will earn ($2.44) per share for the year, down from their previous estimate of ($2.13). […]

Related Keywords

Los Angeles ,California ,United States ,Peter Radovich ,Raymond James ,Jolanda Howe ,Los Angeles Capital Management ,News Ratings For Mirum Pharmaceuticals Daily ,Morgan Stanley ,Raymond James Associates ,Nasdaq ,Insider Activity At Mirum Pharmaceuticals ,Cantor Fitzgerald ,Jump Financial ,Mirum Pharmaceuticals Stock Down ,Securities Exchange Commission ,Campbell Co Investment Adviser ,Institutional Trading Of Mirum Pharmaceuticals ,Rafferty Asset Management ,Mirum Pharmaceuticals ,Mirum Pharmaceuticals Inc ,Jpmorgan Chase Co ,Free Report ,Mirum Pharmaceutical ,Pharmaceuticals Stock Down ,Asset Management ,Angeles Capital Management ,Exchange Commission ,Get Free Report ,Mirum Pharmaceuticals Daily ,Nasdaq Mirm ,Smirm ,Medical ,Earnings Estimates ,Hc Wainwright ,